Biotechnology

AEON Biopharma, Inc.

AEON Biopharma, Inc. released FY2025 9 Months Earnings on November 14 (EST) with actual revenue of USD 0 and EPS of USD 1.2923

AEON Biopharma, Inc. released FY2025 Q3 earnings on November 14 (EST) with actual revenue of USD 0 and EPS of USD -0.39

AEON Biopharma, Inc. released FY2025 Semi-Annual Earnings on August 12 (EST) with actual revenue of USD 0 and EPS of USD 0.3099

AEON Biopharma, Inc. released FY2025 Q2 earnings on August 12 (EST), actual revenue USD 0, actual EPS USD -0.5999

AEON Biopharma Inc. Submits Form 10-K Annual Report Amendment

Jost Fischer Reports Acquisition of AEON Biopharma Shares

AEON Biopharma to Present Company Overview at Virtual Conference

AEON Biopharma, Inc. released FY2025 Q1 earnings on May 14 (EST) with actual revenue of USD 0 and EPS of USD 2.2823

AEON Biopharma, Inc. released FY2024 Q4 earnings on March 24, 2025 (EST), with actual revenue of 0 USD and EPS of 3.4652 USD

AEON Biopharma, Inc. released FY2024 Annual Earnings on March 24 (EST), with actual revenue of 0 USD and EPS of 72.93 USD

AEON Biopharma, Inc. released FY2024 Q3 earnings on November 13, 2024 (EST) with actual revenue of USD 0 and EPS of USD -11.24

AEON Biopharma, Inc. released FY2024 9 Months Earnings on November 13, 2024 (EST) with actual revenue of USD 0 and EPS of USD 64.8886

AEON Biopharma, Inc. released FY2024 Semi-Annual Earnings on August 12 (EST) with actual revenue of 0 USD and EPS of 87.2077 USD

AEON Biopharma, Inc. released FY2024 Q2 earnings on August 12 (EST), actual revenue USD 0, actual EPS USD 304

AEON Pharmaceuticals announces strategic reset to pursue ABP-450 biosimilar approach

AEON Biopharma, Inc. released FY2024 Q1 earnings on May 14 (EST) with actual revenue of USD 0 and actual EPS of USD -227.87

AEON Biopharma, Inc. released FY2023 Q4 earnings on March 29 (EST), with actual revenue of 0 USD and EPS of -50.848 USD

AEON Biopharma, Inc. released FY2023 earnings on March 29 (EST) with actual revenue of 0 USD and EPS of -4.9905 USD

AEON Biopharma, Inc. released FY2023 Q3 earnings on November 13 (EST), with actual revenue of 0 USD and EPS of -388.0461 USD

AEON Biopharma, Inc. released FY2023 9 Months Earnings on November 13 (EST) with actual revenue of 0 USD and EPS of -405.1704 USD

A SPAC III Acquisition

PicoCELA

Davis Commodities

Society Pass

ECD Automotive Design

Gauzy

Bristol-Myers Squibb Company

A SPAC III ACQUISITION CORP. COM NPV CL A (SUBS/RTS)02/01/2026

Paranovus ENT Tech

Cue BioPharma

Please note that a "Suspected value trap" is a stock that appears The stock looks financially sound and severely undervalued, but behind the low valuation is a long-term decline in business capacity or a serious financial crisis, or even the risk of bankruptcy in the short term.

Suspected value trap